AC Immune (ACIU)

AC Immune’s strategy is built around precision medicine. It uses proprietary discovery platforms to design small molecules, monoclonal antibodies, vaccines, and diagnostic agents intended to identify, prevent, or treat disease processes before irreversible neurological damage occurs. Its pipeline includes active and passive immunotherapies as well as candidates designed to support earlier and more targeted diagnosis.

The company’s programs include assets such as ACI-24.060, ACI-35.030, ACI-7104.056, semorinemab, and crenezumab, among others. These candidates address different biological targets and stages of neurodegenerative disease, giving AC Immune a diversified research portfolio within a highly challenging therapeutic area. The company also collaborates with larger pharmaceutical partners on selected programs, a common model in biotechnology where clinical development costs and scientific risk are substantial.

As a clinical-stage company, AC Immune does not resemble a mature pharmaceutical business with a broad portfolio of marketed products. Its investment profile is driven by clinical trial progress, biomarker data, regulatory feedback, partnership activity, cash resources, and the evolving scientific understanding of neurodegeneration. The stock offers exposure to one of medicine’s most important unmet needs, but it also carries the development risk typical of companies working on complex brain diseases.